# SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

Study · id `cardio:ct-nct03982381` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03982381](<https://clinicaltrials.gov/study/NCT03982381>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03982381

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2067 participants.

## Technical summary

Registry record NCT03982381. Randomized; single masking; primary purpose treatment. Start 2019-09-05 (actual); primary completion 2026-01-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2067 participants (enrolled count; ClinicalTrials.gov record NCT03982381, source copy `cardio:ctgov-nct03982381-2026-03-04`, retrieved 2026-10-26)
- Started: 2019-09-05 (actual) (ClinicalTrials.gov record NCT03982381, source copy `cardio:ctgov-nct03982381-2026-03-04`, retrieved 2026-10-26)
- Primary completion: 2026-01-31 (actual) (ClinicalTrials.gov record NCT03982381, source copy `cardio:ctgov-nct03982381-2026-03-04`, retrieved 2026-10-26)
- Completion: 2026-01-31 (actual) (ClinicalTrials.gov record NCT03982381, source copy `cardio:ctgov-nct03982381-2026-03-04`, retrieved 2026-10-26)
- Countries: Sweden (ClinicalTrials.gov record NCT03982381, source copy `cardio:ctgov-nct03982381-2026-03-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03982381-2026-03-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
- Acronym: SMARTEST
- Condition: Type 2 Diabetes
- Intervention (Drug): Metformin
- Intervention (Drug): Dapagliflozin 10 MG
- Lead sponsor: Uppsala University
- Lead sponsor class: OTHER
- Collaborator: Uppsala University Hospital
- Collaborator class: OTHER
- Collaborator: Swedish Healthcare Regions
- Collaborator class: UNKNOWN
- Collaborator: National Board of Health and Welfare, Sweden
- Collaborator class: OTHER\_GOV
- Collaborator: The Swedish National Diabetes Register
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Uppsala University (`cardio:org-uppsala-university`)
- Registry lists this organization as a collaborator: Uppsala University Hospital (`cardio:org-uppsala-university-hospital`)

## Provenance

Content hash: 082c05de619f82b1b5e3e274c0d7d4d3092eb3d5789a5ba74f2456e4cd857830
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
